Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094742 | 0.83 | LTA4H (0.47) | SRD5A2XIAPPTGER1IDO1 | |
| SCHEMBL6096141 | 0.82 | HTR2A (0.44) | HTR2A | |
| SCHEMBL6097211 | 0.79 | HTR2A (0.45) | HTR2ASRD5A2MAOBPTGER1EDNRA | |
| SCHEMBL6099181 | 0.78 | CYP1A2 (0.51) | ACHEMAOB | |
| SCHEMBL6098013 | 0.77 | CLK1 (0.43) | XIAP | |
| SCHEMBL6097121 | 0.76 | HTR2A (0.40) | HTR2AXIAP | |
| SCHEMBL6096750 | 0.76 | GPR84 (0.40) | XIAPIDO1 | |
| SCHEMBL6097228 | 0.76 | FFAR1 (0.40) | HTR2AXIAP | |
| SCHEMBL9085416 | 0.75 | PRKCB (0.59) | HTR2A | |
| SCHEMBL6097125 | 0.72 | PRKCB (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057052-B2 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2004050014-A2 | SETEROCYCLIC QUINONES AS PHARMACEUTICAL AGENTS | DUKE UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | NQO1, RECQL, SDHA | HTR2A 1843/4885SRD5A2 2189/4885XIAP 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.